Acumen Pharma Reports Positive Trial Results Of ACU193 In Early Alzheimer's Disease
17/7 09:37
(RTTNews) - Acumen Pharmaceuticals, Inc. (ABOS), a clinical-stage biopharmaceutical company, Monday announced positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomer or AßO targeting antibody therapy in early Alzheime...